When was MediPrint founded?

MediPrint was founded in 2001 and raised its 1st funding round 19 years after it was founded.

Where is MediPrint located?

MediPrint is headquartered in San Diego, United States.

How many employees does MediPrint have?

As of Jun 30, 2026, the latest employee count at MediPrint is 13.

Is MediPrint a funded company?

MediPrint is a funded company, having raised a total of $11.4M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 09, 2020.

When was the latest funding round of MediPrint?

MediPrint's latest funding was a $***** Series A round on Mar 15, 2022, with participation from 0 investor. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $1.37B in funding in 2026 to date.

Where does MediPrint rank among its competitors?

MediPrint ranks 7th amongst 37 active competitors, of which 13 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Eyenovia, which secured $50M in Jun, 2025.

Who are the top competitors of MediPrint?

MediPrint's top competitors include Eyenovia, Re-Vana Therapeutics and PolyActiva. Among them, Eyenovia secured the most recent funding round in June, 2025.

MediPrint - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of technology for ocular drug delivery. The company has developed proprietary printing technology and ink that allows sustained, continuous release of ophthalmic drugs via contact lenses to treat glaucoma, dry eye, myopia, and others.

Website: mediprintlens.com
Email ID: *****@leolens.com
Phone Number: +1 **********

Key Metrics

Founded Year

2001

Location

San Diego, United States

Stage

Series A

Total Funding

$11.4M in 3 rounds

Latest Funding Round

Series A, Mar 15, 2022, $*****

Ranked

7^th among 37 active competitors

Employee Count

13 as on Jun 30, 2026

Similar Companies

Eyenovia & 39 more

View MediPrint's full profile

MediPrint has raised a total funding of $11.4M over 3 rounds. Its first funding round was on Dec 09, 2020.

Here is the list of recent funding rounds of MediPrint:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 15, 2022	6031352	Series A	5500806	3283240	2926530	6993614
Jan 26, 2021	3853264	Series A	8092336	5863991	7487682	8792120
Dec 09, 2020	3294138	Series A	2854112	7214360	3280690	1139643

Access funding benchmarks and valuations. Sign up today!

View details of MediPrint's funding rounds and investors

MediPrint's employee count trend

MediPrint has 13 employees as of Jun 26. Here is MediPrint's employee count trend over the years:

Uncover MediPrint's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MediPrint include Eyenovia, Re-Vana Therapeutics and PolyActiva. Here is the list of Top 10 competitors of MediPrint, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Eyenovia 2014, New York City (United States), Public	Developer of microdose therapies for treating myopia	$10M	Senju Pharmaceutical, Eshelman Ventures & 3 others	62/100
2nd	Re-Vana Therapeutics 2015, Belfast (United Kingdom), Series A	Developer of drug delivery platform forophthalmic diseases	$16.8M	Visionary Ventures, Exsight Ventures & 11 others	55/100
3rd	PolyActiva 2010, Melbourne (Australia), Series C	Drug delivery platform	$46.7M	National Reconstruction Fund, Brandon Capital ... & 2 others	55/100
4th	Everads Therapy 2017, Tel Aviv (Israel), Funding Raised	Drug & a cell targeting system for posterior segment eye diseases	-	EIC Fund, Europa & 1 others	45/100
5th	Kedalion Thera 2015, Menlo Park (United States), Acquired	Provider of drug delivery system for eye diseases	$5M	Novartis, Lagunita Biosciences	44/100
6th	LayerBio 2013, Boston (United States), Acquired	Developing innovative ophthalmic therapies, including sustained-release drug delivery for cataract surgery	$205K	C2I Accelerator, HHS & 1 others	43/100
7th	MediPrint 2001, San Diego (United States), Series A	Developer of technology for ocular drug delivery	$11.4M	-	37/100
8th	Opharmic 2016, Hong Kong (China), Funding Raised	Developer of non-invasive ocular drug delivery system	-	MedTech Innovator, Pentepebble	35/100
9th	VisusNano 2016, Stevenage (United Kingdom), Seed	Developer of drug-eluting intraocular lens implants	$377K	Discovery Park Ventures, LCIF & 17 others	34/100
10th	Amorphex 2010, Andover (United States), Seed	Developer of drug delivery device for ophthalmic diseases	$265K	-	33/100